These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 23241931)

  • 1. Meriva®, a lecithinized curcumin delivery system, in the control of benign prostatic hyperplasia: a pilot, product evaluation registry study.
    Ledda A; Belcaro G; Dugall M; Luzzi R; Scoccianti M; Togni S; Appendino G; Ciammaichella G
    Panminerva Med; 2012 Dec; 54(1 Suppl 4):17-22. PubMed ID: 23241931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Meriva®, a lecithinized curcumin delivery system, in diabetic microangiopathy and retinopathy.
    Steigerwalt R; Nebbioso M; Appendino G; Belcaro G; Ciammaichella G; Cornelli U; Luzzi R; Togni S; Dugall M; Cesarone MR; Ippolito E; Errichi BM; Ledda A; Hosoi M; Corsi M
    Panminerva Med; 2012 Dec; 54(1 Suppl 4):11-6. PubMed ID: 23241930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potential role of curcumin phytosome (Meriva) in controlling the evolution of diabetic microangiopathy. A pilot study.
    Appendino G; Belcaro G; Cornelli U; Luzzi R; Togni S; Dugall M; Cesarone MR; Feragalli B; Ippolito E; Errichi BM; Pellegrini L; Ledda A; Ricci A; Bavera P; Hosoi M; Stuard S; Corsi M; Errichi S; Gizzi G
    Panminerva Med; 2011 Sep; 53(3 Suppl 1):43-9. PubMed ID: 22108476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A naturally-inspired, curcumin-based lecithin formulation (Meriva® formulated as the finished product Algocur®) alleviates the osteo-muscular pain conditions in rugby players.
    Di Pierro F; Zacconi P; Bertuccioli A; Togni S; Eggenhoffner R; Giacomelli L; Scaltrini S
    Eur Rev Med Pharmacol Sci; 2017 Nov; 21(21):4935-4940. PubMed ID: 29164565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical impact of tamsulosin on generic and symptom-specific quality of life for benign prostatic hyperplasia patients: using international prostate symptom score and Rand Medical Outcomes Study 36-item Health Survey.
    Suzuki H; Yano M; Awa Y; Nakatsu H; Egoshi K; Mikami K; Ota S; Okano T; Hamano S; Ohki T; Furuya Y; Ichikawa T
    Int J Urol; 2006 Sep; 13(9):1202-6. PubMed ID: 16984553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bipolar plasma enucleation of the prostate vs open prostatectomy in large benign prostatic hyperplasia cases - a medium term, prospective, randomized comparison.
    Geavlete B; Stanescu F; Iacoboaie C; Geavlete P
    BJU Int; 2013 May; 111(5):793-803. PubMed ID: 23469933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Quality of life assessment of the male with benign prostate hypertrophy].
    Nekić VC; Tiljak H; Petricek G; Soldo D; Nekić G; Buljan N
    Acta Med Croatica; 2007 Feb; 61(1):49-55. PubMed ID: 17593641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Comparison of self-estimation of disuric disorders gauged IPSS scale and qualities of lives QoL with self-estimation of sexual life gauged by IIEF-5 scale].
    Lipczyński W; Dobrowolska-Glazar B; Dobrowolski ZF
    Przegl Lek; 2012; 69(6):247-52. PubMed ID: 23094437
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation of the International Prostate Symptom Score bother question with the Benign Prostatic Hyperplasia Impact Index in a clinical practice setting.
    O'Leary MP; Wei JT; Roehrborn CG; Miner M;
    BJU Int; 2008 Jun; 101(12):1531-5. PubMed ID: 18445080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score.
    Kaplan SA; Roehrborn CG; Chancellor M; Carlsson M; Bavendam T; Guan Z
    BJU Int; 2008 Nov; 102(9):1133-9. PubMed ID: 18510659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of combined therapy with terazosin and tolteradine for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective study.
    Yang Y; Zhao XF; Li HZ; Wang W; Zhang Y; Xiao H; Zhang X
    Chin Med J (Engl); 2007 Mar; 120(5):370-4. PubMed ID: 17376305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of branded versus generic terazosin hydrochloride in adults with benign prostatic hyperplasia: a randomized, open-label, crossover study in Taiwan.
    Tsai YS; Lan SK; Ou JH; Tzai TS
    Clin Ther; 2007 Apr; 29(4):670-82. PubMed ID: 17617290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between lower urinary tract symptoms and erectile dysfunction.
    Aslan G; Cavus E; Karas H; Oner O; Duran F; Esen A
    Arch Androl; 2006; 52(3):155-62. PubMed ID: 16574595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe.
    Chapple CR; Montorsi F; Tammela TL; Wirth M; Koldewijn E; Fernández Fernández E;
    Eur Urol; 2011 Mar; 59(3):342-52. PubMed ID: 21109344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Profile and management of patients treated for the first time for lower urinary tract symptoms/benign prostatic hyperplasia in four European countries.
    Fourcade RO; Théret N; Taïeb C;
    BJU Int; 2008 May; 101(9):1111-8. PubMed ID: 18279447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: a 3-year experience in real-life practice.
    Vallancien G; Emberton M; Alcaraz A; Matzkin H; van Moorselaar RJ; Hartung R; Harving N; Elhilali M;
    BJU Int; 2008 Apr; 101(7):847-52. PubMed ID: 18321317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Product-evaluation registry of Meriva®, a curcumin-phosphatidylcholine complex, for the complementary management of osteoarthritis.
    Belcaro G; Cesarone MR; Dugall M; Pellegrini L; Ledda A; Grossi MG; Togni S; Appendino G
    Panminerva Med; 2010 Jun; 52(2 Suppl 1):55-62. PubMed ID: 20657536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Change in International Prostate Symptom Score, prostrate-specific antigen and prostate volume in patients with benign prostatic hyperplasia followed longitudinally.
    Tsukamoto T; Masumori N; Rahman M; Crane MM
    Int J Urol; 2007 Apr; 14(4):321-4; discussion 325. PubMed ID: 17470162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study.
    Nishino Y; Masue T; Miwa K; Takahashi Y; Ishihara S; Deguchi T
    BJU Int; 2006 Apr; 97(4):747-51, discussion 751. PubMed ID: 16536766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-year results from the randomized, double-blind Combination of Avodart and Tamsulosin (CombAT) trial.
    Roehrborn CG; Barkin J; Siami P; Tubaro A; Wilson TH; Morrill BB; Gagnier RP
    BJU Int; 2011 Mar; 107(6):946-54. PubMed ID: 21332630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.